You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 5, 2024

CLINICAL TRIALS PROFILE FOR MESALAMINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Mesalamine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00063414 ↗ ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis Completed Ionis Pharmaceuticals, Inc. Phase 2 1969-12-31 This is a multi-center trial to test the safety, efficacy and tolerability of alicaforsen (ISIS 2302), a new type of drug called an antisense drug, in patients with mild to moderate active Ulcerative Colitis (UC). Alicaforsen is designed to reduce the production of a specific protein, called ICAM-1, a substance that plays a significant role in the increase of inflammation and is likely to be involved in inflammatory bowel diseases such as ulcerative colitis. The ISIS 2302-CS22 study will examine the effects of one of two dosages of alicaforsen delivered by enema over a six-week period as compared to an active control, mesalamine enema (The probability of receiving the alicaforsen formulation is 2:1). The primary objective of this study is to evaluate the percentage reduction in DAI at Week 6.
NCT00098111 ↗ Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease Terminated Massachusetts General Hospital Phase 3 2005-04-01 The purpose of this study is to identify an optimal weight based dose of azathioprine that is safe and effective in the treatment of subjects with active Crohn's disease requiring treatment with corticosteroids, and for maintaining remission in those subjects.
NCT00109473 ↗ Trial of Growth Hormone Therapy in Pediatric Crohn's Disease Completed Genentech, Inc. Phase 2 2005-04-01 The purpose of this study is to determine whether taking a growth hormone (GH) drug called somatropin causes the intestine of a person with Crohn's Disease (CD) to heal faster when compared to a person with Crohn's Disease that does not receive growth hormone drug.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Mesalamine

Condition Name

Condition Name for Mesalamine
Intervention Trials
Ulcerative Colitis 38
Healthy 10
Inflammatory Bowel Diseases 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Mesalamine
Intervention Trials
Colitis 56
Colitis, Ulcerative 54
Ulcer 47
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Mesalamine

Trials by Country

Trials by Country for Mesalamine
Location Trials
United States 432
Canada 35
India 28
Poland 22
Italy 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Mesalamine
Location Trials
Florida 23
California 21
Texas 21
Georgia 18
Ohio 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Mesalamine

Clinical Trial Phase

Clinical Trial Phase for Mesalamine
Clinical Trial Phase Trials
Phase 4 11
Phase 3 30
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Mesalamine
Clinical Trial Phase Trials
Completed 57
Terminated 16
Not yet recruiting 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Mesalamine

Sponsor Name

Sponsor Name for Mesalamine
Sponsor Trials
Shire 11
Valeant Pharmaceuticals International, Inc. 8
Bausch Health Americas, Inc. 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Mesalamine
Sponsor Trials
Other 77
Industry 74
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.